Importance of Grant Funding to SMEs in the UK: Its Continuance through Brexit

Importance of Grant Funding to SMEs in the UK: Its Continuance through Brexit
“Grants increase our reach - both financially and technically”

We are developing three key technologies here in Ortheia and JRI:

  • Regenerative Therapy for the Hip – Codename: Hummingbird
  • In-Theatre Manufacturing – Codename: CONSTRUCt
  • Bone / Implant Interface – Codename: INTEGRATE

These are enabled through the far-sighted grant programmes to which we have access. e.g. through Innovate UK and Horizon 2020.

It is important that this range of funding remains open to us as we go through the Brexit process and into the future.

Read More

Exploiting UK Inventions in the UK: The Ortheia Innovation Model

Exploiting UK Inventions in the UK: The Ortheia Innovation Model

In my recent blog “UK, Nation of Inventions Exploited by Others” I argued that my main concern as an Innovation Director in the MedTech is beyond the priorities outlined in the Life Sciences Industry Strategy papers and is:

  • UK is historically not good at getting new Life Sciences technologies to patients

My point was that while we as a nation revel in the magnificence of our top Universities, we have not learnt from others that innovation requires active and concerted efforts to achieve commercial success. We look to our Ivory Towers to not only break new scientific or technological grounds but also, miraculously, launch them and start treating patients.

Read More

Key Future Success Factor: Common Regulations in Europe

Key Future Success Factor: Common Regulations in Europe

I was heartened to read in the report “Maintaining and growing the UK’s world leading Life Sciences sector in the context of leaving the EU” from the UK EU Life Sciences Steering Group that there was emphasis on the importance of keeping a common European regulatory system after Brexit. 

Read More